97 related articles for article (PubMed ID: 16170195)
21. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
23. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
24. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
25. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1452-9. PubMed ID: 20605368
[TBL] [Abstract][Full Text] [Related]
26. Optimal chemotherapy for high-risk early-stage breast cancer.
Atkins CD
J Clin Oncol; 2010 Jun; 28(16):e263; author reply e264. PubMed ID: 20406917
[No Abstract] [Full Text] [Related]
27. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Bonneterre J; Tubiana-Hulin M; Catimel G
Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
[No Abstract] [Full Text] [Related]
29. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
[No Abstract] [Full Text] [Related]
30. Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Hawkes EA; Okines AF; Plummer C; Cunningham D
J Clin Oncol; 2011 Jun; 29(18):e560-2. PubMed ID: 21606423
[No Abstract] [Full Text] [Related]
31. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
[TBL] [Abstract][Full Text] [Related]
32. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Wang B; Fu JF; Hong ZW
Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
[TBL] [Abstract][Full Text] [Related]
34. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].
Thomssen C
Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443
[No Abstract] [Full Text] [Related]
35. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Riccardi A; Pugliese P; Danova M; Brugnatelli S; Grasso D; Giordano M; Bernardo G; Giardina G; Fava S; Montanari G; Pedrotti C; Trotti G; Rinaldi E; Poli MA; Tinelli C
Br J Cancer; 2001 Jul; 85(2):141-6. PubMed ID: 11461067
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy protocol with taxol increase survival by 31 percent].
Krankenpfl J; 2002; 40(7-9):226. PubMed ID: 12514866
[No Abstract] [Full Text] [Related]
38. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
39. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Watanabe N; Ootawa Y; Kodama K; Kaide A; Ootsuka N; Matsuoka J
Breast Cancer; 2010 Oct; 17(4):247-53. PubMed ID: 19728030
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab/navelbine produces encouraging results in early breast cancer patients.
Oncology (Williston Park); 2003 Sep; 17(9):1224. PubMed ID: 14569850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]